Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non Follicular Indolent Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)UnknownNCT01698866
What this trial is testing

Low Grade Lymphoma

Who this might be right for
Indolent Lymphoproliferative Disorders
Central Hospital, Nancy, France 40
Testing effectiveness (Phase 2)WithdrawnNCT01238146
What this trial is testing

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular Lymphoma+4 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT03498612
What this trial is testing

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Who this might be right for
Follicular LymphomaIndolent B-Cell Non-Hodgkin LymphomaMarginal Zone Lymphoma
University of Washington 9
Testing effectiveness (Phase 2)Study completedNCT00085696
What this trial is testing

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Who this might be right for
B-Cell LymphomaFollicular LymphomaMarginal Lymphoma
Millennium Pharmaceuticals, Inc. 66
Early research (Phase 1)Active Not RecruitingNCT04323956
What this trial is testing

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Who this might be right for
Ann Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone Lymphoma+11 more
Mayo Clinic 50
Large-scale testing (Phase 3)UnknownNCT02991638
What this trial is testing

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Who this might be right for
Chronic Lymphocytic LeukemiaIndolent B-cell LymphomasChronic Hepatitis B+4 more
The University of Hong Kong 62
Early research (Phase 1)Study completedNCT00082784
What this trial is testing

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Who this might be right for
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaRecurrent Adult Diffuse Large Cell Lymphoma+10 more
National Cancer Institute (NCI) 93
Early research (Phase 1)WithdrawnNCT04836832
What this trial is testing

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Nodal Marginal Zone Lymphoma+6 more
Narendranath Epperla
Testing effectiveness (Phase 2)Study completedNCT00005579
What this trial is testing

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
University of Vermont
Early research (Phase 1)Study completedNCT00052416
What this trial is testing

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
Beth Israel Deaconess Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT00110149
What this trial is testing

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Beth Israel Deaconess Medical Center 12
Early research (Phase 1)Study completedNCT00060684
What this trial is testing

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Low-GradeLymphoma, Small LymphocyticLymphoma, Mixed-Cell, Follicular+1 more
CTI BioPharma 30
Testing effectiveness (Phase 2)Study completedNCT01926639
What this trial is testing

Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma

Who this might be right for
Follicular Lymphoma
Oslo University Hospital 14
Large-scale testing (Phase 3)Ended earlyNCT00060671
What this trial is testing

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, FollicularLymphoma, Mixed-Cell, FollicularLymphoma, Small Cleaved-Cell, Follicular+1 more
CTI BioPharma 800
Not applicableStudy completedNCT00574730
What this trial is testing

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
University of Nebraska 27
Testing effectiveness (Phase 2)Study completedNCT00875056
What this trial is testing

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Who this might be right for
Lymphoma
Merck Sharp & Dohme LLC 56
Large-scale testing (Phase 3)WithdrawnNCT02576275
What this trial is testing

Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Who this might be right for
Indolent Non-Hodgkin's LymphomaFollicular LymphomaSmall Lymphocytic Lymphoma+1 more
SecuraBio
Early research (Phase 1)Looking for participantsNCT04223765
What this trial is testing

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Who this might be right for
Mantle Cell LymphomaFollicular LymphomaSplenic Marginal Zone Lymphoma+3 more
UNC Lineberger Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)WithdrawnNCT00004039
What this trial is testing

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT03105336
What this trial is testing

Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaIndolent Non-Hodgkin Lymphoma
Kite, A Gilead Company 159
Next Page